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        Platelet activation is critical for the termination of 
bleeding after injury. In diseased vessels, plate-
lets contribute to thrombus formation, leading 
to vessel occlusion and tissue infarction. Two 
receptors promote platelet activation through 
distinct but complementary roles: glycoprotein 
VI (GPVI), which together with integrin     2    1 
binds collagen, and integrin     IIb    3, which rec-
ognizes several ligands, including fi  brinogen and 
von Willebrand factor (  1  ). 
  GPVI associates with the immunoreceptor 
tyrosine-based activation motif (ITAM)  –  con-
taining FcR    , which undergoes phosphoryl-
ation by Src family protein tyrosine kinases 
(PTKs) after GPVI cross-linking. Once phos-
phorylated, the FcR     ITAM binds and acti-
vates Syk, initiating a signaling cascade that 
results in platelet spreading, secretion of soluble 
mediators, and aggregation (  2  ). For platelet ag-
gregate stabilization under the shear fl  ow con-
ditions of the blood vessels, activation of    IIb    3 
is required. In resting platelets,     IIb    3 is pre-
sent in a low-affi   nity state and is unable to bind 
soluble ligands. Agonist-initiated intracellular 
signals result in increased affi   nity of     IIb    3, a 
process known as inside-out signaling. Ligand 
binding to activated     IIb    3 then generates a 
second wave of PTK-initiated signals, known 
as outside-in signaling, that promotes fi  rm platelet 
adhesion and spreading. The adaptor protein 
Src homology 2 (SH2) domain  –  containing leu-
kocyte phosphoprotein of 76 kD (SLP76) is 
central to the signaling pathways induced by 
engagement of GPVI and     IIb    3. 
  SLP76 was originally described as a regula-
tor of TCR signaling (  3, 4  ), and it functions 
as a scaff  old to nucleate a multimolecular com-
plex after TCR engagement (  5  ). SLP76 was sub-
sequently shown to be important for signaling 
in other hematopoietic lineages, including 
platelets. Platelets from SLP76      /      animals do 
not couple GPVI engagement with activation 
of the downstream signaling cascade, resulting 
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  Src homology 2 domain  –  containing leukocyte phosphoprotein of 76 kD (SLP76), an adap-
tor that plays a critical role in platelet activation in vitro, contains three N-terminal 
tyrosine residues that are essential for its function. We demonstrate that mice containing 
complementary tyrosine to phenylalanine mutations in Y145 (Y145F) and Y112 and Y128 
(Y112/128F) differentially regulate integrin and collagen receptor signaling. We show 
that mutation of Y145 leads to severe impairment of glycoprotein VI (GPVI)  –  mediated 
responses while preserving outside-in integrin signaling. Platelets from Y112/128F mice, 
although having mild defects in GPVI signaling, exhibit defective actin reorganization 
after GPVI or     IIb    3 engagement. The in vivo consequences of these signaling defects 
correlate with the mild protection from thrombosis seen in Y112/128F mice and the near 
complete protection observed in Y145F mice. Using genetic complementation, we further 
demonstrate that all three phosphorylatable tyrosines are required within the same SLP76 
molecule to support platelet activation by GPVI. 
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tered to phenylalanine are born at Mendelian ratios, have no 
overt vascular phenotype, and have normal platelet counts 
(  24  ). Therefore, we used these animals to probe the impor-
tance of SLP76 and, in particular, its N-terminal tyrosines 
for in vivo platelet function. 
  WT or KI mice expressing SLP76 containing either com-
bined mutations in Y112 and Y128 (Y112/128F mice) or a 
single mutation in Y145 (Y145F mice) were studied in a 
model of arterial thrombosis (  Fig. 1  ).   For these experiments, 
the carotid artery was exposed for thrombus induction by 
topical application of 10% FeCl  3  , a protocol that leads to local 
denudation of the vessel endothelium and exposure of colla-
gen fi  bers (  25  ). To monitor vessel occlusion, a Doppler fl  ow 
probe was used to measure the rate of blood fl  ow through the 
artery, with each experiment lasting 30 min after application 
of the irritant. A fl  ow rate   <  0.1 ml/min for the duration of 
the study was scored as a stable occlusive thrombus. Animals 
in which blood fl  ow stopped but then resumed were scored 
as having an unstable thrombus. 
  In 100% of WT mice of either a pure C57BL/6 or a 
mixed C57BL6/129Sv background (littermate controls for 
KI animals), stable occlusive thrombi formed at 7.1   ±   0.6 or 
7.5   ±   1.1 min after injury, respectively (  Fig. 1 B  ). In contrast, 
69% (9 out of 13) of Y145F mice never formed a thrombus 
after injury. Among the four mice that did occlude, the time 
to initial occlusion was delayed (14.9   ±   2.4 min), and two of 
these animals formed unstable thrombi that embolized soon 
after formation (  Fig. 1 B  ). Y112/128F mice showed a milder 
defect in thrombus formation, with 25% (3 out of 12) failing 
to occlude blood fl  ow. 
  To visualize platelet aggregation, we modeled thrombus 
formation ex vivo by examining platelet dynamics under 
physiological fl  ow conditions. Platelets in whole blood were 
perfused over collagen at variable shear rates from 400 to 
1,300 s      1   for 4 min. Blood from WT mice exhibited robust 
accumulation of densely packed platelets on collagen (  Fig. 
1 C  ). Y145F platelets adhered less well to collagen (33.3   ±   
2.3% surface coverage by Y145F platelets vs. 50.3   ±   1.9% 
surface coverage by WT platelets), and the overall thrombus 
volume was markedly reduced (0.3   ×   10  5     ±   0.06   ×   10  5     μ  m  3   
compared with 10  5     ±   0.06   ×   10  5     μ  m  3   as measured from WT 
samples;   Fig. 1, D and E  ). Platelets from the Y112/128F mice 
effi   ciently covered the collagen surface (  Fig. 1 E  ); however, 
the overall thrombus volume (0.8   ×   10  5     ±   0.1   ×   10  5     μ  m  3  ) 
tended to be smaller than that seen with WT platelets. Col-
lectively, these data suggest that only Y145 is necessary for 
fi  rm adhesion to collagen; however, mutation of either Y145 
or combined mutations of Y112 and Y128 impairs signaling 
events necessary for the formation of tight platelet aggregates 
under fl  ow. These data make it clear that other regions of 
SLP76 are important for platelet adhesion and aggregate for-
mation on collagen, as the analysis of platelets isolated from 
SLP76      /      mice revealed a much more dramatic phenotype 
with very few platelets adhering to collagen (0.09   ±   0.01% 
surface coverage at 1,300 s      1  ) and with a complete absence of 
detectable aggregates (0.01   ±   0.001   μ  m  3  ). 
in failed degranulation or aggregation in response to collagen 
(  6, 7  ). SLP76      /      platelets show a marked reduction in spread-
ing when adhered to a fi  brinogen-coated surface, indicating 
that SLP76 is critical for signaling downstream of     IIb    3 (  8  ). 
These in vitro defects suggested that SLP76 was important for 
platelet function in vivo. However, it had not been feasible 
to test this question given the vascular development abnor-
malities of SLP76      /      mice that lead to signifi  cant hemody-
namic compromise (  9  ). 
  SLP76 is composed of four modular domains: a C-termi-
nal SH2 domain, a proline-rich region, a sterile      motif 
domain, and an N-terminal acidic domain that contains three 
tyrosine phosphorylation motifs (Y  112  ESP, Y  128  ESP, and 
Y  145  EPP). Phosphorylated Y112 and Y128 are recognized by 
SH2 domain  –  containing proteins, including Vav (  10  –  14  ) and 
noncatalytic region of tyrosine kinase (  15, 16  ). Y145 is rec-
ognized by the Tec family kinases IL-2  –  inducible T cell 
kinase (Itk) and Bruton  ’  s tyrosine kinase (Btk) (  17, 18  ). The 
critical role of these N-terminal tyrosines for SLP76 function 
was initially shown in T cells, where SLP76 with a mutation 
in all three tyrosines (Y3F) was unable to rescue TCR signal-
ing in SLP76      /      Jurkat cells and failed to rescue T cell devel-
opment in SLP76      /      mice (  19  –  21  ). Retroviral transduction 
of SLP76-defi  cient bone marrow with the Y3F mutant fol-
lowed by transplant into irradiated recipients resulted in the 
development of platelets with defects in GPVI and     IIb    3 
signaling (  22  ). The precise mechanism by which these N-
terminal tyrosines contribute to SLP76 function during plate-
let activation is not well understood. 
  In this paper, we explore the role of these tyrosines in 
platelet function in vitro and in vivo. Our data indicate that 
SLP76 Y145 is essential for normal thrombus formation in a 
model of arterial injury and that mutation of either Y145 or 
both Y112 and Y128 results in signifi  cant alterations in 
signaling downstream of GPVI and     IIb    3. Generation of 
knock-in (KI) mice with mutations in SLP76 tyrosines al-
lowed us to ask whether these phosphorylation sites act inde-
pendently or in combination during SLP76 function. Using a 
genetic complementation approach, we fi  nd that all three 
phosphorylatable tyrosines are required within the same 
SLP76 molecule for platelet activation. 
    RESULTS   
  Mice with mutant SLP76 tyrosines are resistant 
to thrombus formation 
  Although we and others have documented severe signaling 
defects in platelets from SLP76-defi  cient mice (  6, 23  ), it has 
been impossible to assess the consequences of SLP76 defi  -
ciency on platelet function in vivo, because mice lacking 
this adaptor protein manifest a severe vascular abnormality 
associated with cardiac hypertrophy, altered hemodynamics, 
and abnormal connections between blood and lymphatic 
vessels (  9  ). This vascular defect is also present in mice in 
which an SLP76 Y3F mutant is expressed (  22  ). Recently, 
we found that mice in which two of these tyrosines (Y112 
and Y128) or an individual tyrosine (Y145) have been al-JEM VOL. 205, August 4, 2008 
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low-dose collagen (2.5   μ  g/ml;   Fig. 2 A  ).   Raising the collagen 
concentration increased aggregation in cells from both KI an-
imals; however, platelets from Y145F mice required a much 
higher collagen concentration (10 vs. 3.3   μ  g/ml) to reconsti-
tute a normal response ( Fig. 2, A and C ). In contrast, SLP76      /      
platelets manifested a barely detectable response, even to the 
  SLP76 Y145 is critical for GPVI-induced aggregation 
  To investigate the mechanism underlying the defect in throm-
bus formation in SLP76 KI mice, we tested whether Y145F 
or Y112/128F platelets aggregate in solution in response to 
collagen. Similar to SLP76      /      platelets, Y145F or Y112/128F 
platelets showed a marked defect in aggregation in response to 
    Figure 1.     Impaired thrombus formation in mice with mutations in SLP76 tyrosines.   (A) Schematic of SLP76 KI mice. (B) Thrombus formation in Y112/
128F (  n   = 12), Y145F (  n   = 13), WT littermate control (  n   = 16), or C57BL/6 (  n   = 8) mice after FeCl  3  -induced injury of the carotid artery. Representative fl  ow traces 
for each genotype are shown, and arrows indicate when 10% FeCl  3   was applied. The time to vessel occlusion in individual mice for each group is shown in the 
scattergram. Symbols above the 30-min threshold represent mice that had not occluded when the experiment was terminated. Horizontal bars show the mean 
occlusion time for WT animals. Unstable mice (U) formed a transient occlusion that resolved. Ratios of the number of animals that did not form occlusion to the 
number of animals that did were compared between WT and SLP76 KI mice using Fisher  ’  s exact test. (C) Platelets in whole blood were perfused over collagen-
coated slides at variable shear rates for 4 min (  n   = 3). Representative phase-contrast images after perfusion are shown (top, shear rate = 400 s     1  ; bottom, shear 
rate = 1,300 s     1  ). Bar, 10   μ  m. (D and E) Thrombus volume (D) and thrombi surface area (E) were measured at a shear rate of 1,300 s     1   at  fi  ve surface locations 
(mean   ±   SEM). Statistical analysis was performed using the Student  ’  s   t   test. *, P   <   0.05; and **, P   <   0.01 for differences between mutant and WT platelets.    1778 SLP76 TYROSINES IN PLATELET FUNCTION   | Bezman et al. 
in Y145F and Y112/128F platelets is caused by impaired sig-
nals from one or both of these receptors. We measured aggre-
gation in platelets stimulated with the GPVI agonist convulxin 
(CVX). Before proceeding with the analysis, we confi  rmed 
that the cell-surface expression of GPVI is equivalent between 
SLP76 KI and WT platelets (unpublished data). Y112/128F 
highest dose of collagen stimulation, indicating that the Y145 
mutation or the combined Y112/Y128 mutation results in a 
reduction but not a complete loss of SLP76 function. 
  Because two receptors, GPVI and     2    1, function to-
gether to activate platelets in response to collagen (  26  ), we in-
vestigated whether the defect in collagen-induced aggregation 
    Figure 2.     Y145F mutation inhibits GPVI-mediated platelet aggregation.   (A  –  D) Platelets were stimulated with various doses of collagen (A) or CVX 
(B), and aggregation was assessed for 5 min. Representative aggregation tracings are shown. Quantifi  cation of the maximum percentage of aggregation 
in SLP76 mutant versus WT platelets in response to collagen (C) or CVX (D) are shown. Each point is the mean   ±   SEM of three to seven experiments, and 
the difference between Y145F and WT is signifi  cant. *, P   <   0.05; **, P   <   0.01. (E) WT or KI platelets were pretreated with the anti-    2 antibody Ha1/29 (red) 
or DMSO (black), and aggregation was measured (  n   =  2).   JEM VOL. 205, August 4, 2008 
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combined Y112/128F mutation resulted in a smaller increase 
in fi  brinogen binding relative to WT cells (9.6   ±   0.5  –   vs. 14.8   ±   
0.9  –  fold induction relative to the resting state), a response 
that was absent in SLP76      /      platelets. The Y145F mutation 
dramatically reduced the ability of GPVI signaling to couple 
to increased fi  brinogen binding (5.6   ±   2.6  –  fold induction 
relative to the resting state). This defect is not caused by di-
minished levels of the integrin, because all genotypes showed 
similar level of     3 surface expression (unpublished data). 
Furthermore, all cells bound fi  brinogen similarly after activa-
tion with ADP, an agonist that induces     IIb    3 activation in 
an SLP76-independent manner. 
  SLP76 tyrosines are critical for GPVI-induced 
phosphorylation of Btk and phospholipase C     2 (PLC    2) 
  To investigate the molecular basis of the activation defect in 
SLP76 KI platelets, we measured tyrosine phosphorylation 
events occurring downstream of GPVI engagement. Stimu-
lation of WT cells with CVX led to a dramatic increase in 
SLP76 phosphorylation using the panphosphotyrosine-spe-
cifi  c antibody 4G10 (  Fig. 4 A  , lane 2).   In SLP76 Y112/128F 
cells, phosphorylation of Y145 was greatly diminished (lane 
4). Because residues 112, 128, and 145 are the only tyrosine 
phosphorylation sites detected by 4G10 antibody (  27  ), these 
results indicate a dependency of intact Y112 and/or Y128 
for optimal Y145 phosphorylation. Furthermore, Y145 and 
Y128 show cooperation in phosphorylation of Y128. Using 
a phospho-specifi  c antibody to Y128, we found a decrease in 
Y128 phosphorylation in Y145F platelets (bottom blot, lane 
2 vs. lane 6). In fi  ve separate experiments, quantifi  cation of 
Y128 phosphorylation revealed a decrease ranging from 30 
to 50%. These data suggest that the diminished phosphoryl-
ation of SLP76 from the Y145F cells observed using 4G10 
(top blot, lane 2 vs. lane 6) is likely caused by loss of Y145 
and diminished phosphorylation of Y128. This reduction in 
the phosphorylation of specifi  c tyrosine residues is not caused 
by diminished levels of SLP76 expression (top and bottom 
blots, lane 2 vs. lanes 4 and 6). The altered phosphorylation 
of the SLP76 mutants is also not caused by decreased PTK 
activity, as activation of Syk and phosphorylation of its sub-
strate linker for activation of T cells (LAT) are not aff  ected 
in the SLP76 KI platelets (  Fig. 4 B  ). 
  Activation of PLC    2 is a critical SLP76-dependent bio-
chemical signal after GPVI stimulation. To examine whether 
Y112 plus Y128 or Y145 are necessary for PLC    2 activation, 
we examined the PLC    2 phosphorylation status in platelets 
from the various mice after stimulation with a moderate dose 
of CVX. WT platelets showed signifi  cant PLC    2 phosphoryl-
ation induction, whereas this response was not detected in the 
absence of SLP76 (  Fig. 4 C  ). Both tyrosine mutants exhibited 
diminished PLC    2 phosphorylation; however, Y145F cells 
consistently exhibited a more profound phenotype than that 
observed in Y112/128F cells (  Fig. 4 C  ). Because a high CVX 
concentration (1 nM) induces a nearly normal aggregation re-
sponse in Y112/128F but not in Y145F platelets, we investi-
gated the dose dependency of CVX on GPVI-induced PLC    2 
platelets exhibited a mild reduction in CVX-induced aggre-
gation, with the diff  erence compared with WT cells greatest 
at the lowest (0.2 nM) dose of agonist (  Fig. 2, B and D  ). Strik-
ingly, aggregation of Y145F platelets was completely abolished, 
with only a minor shape change in response to the highest 
concentrations (1 nM) of CVX. SLP76      /      platelets exhibited 
minimal responses to high-dose CVX (as high as 5 nM was 
tested). To ensure that the abnormal responses were re-
stricted to SLP76-dependent pathways, we stimulated platelets 
from all mice with two G protein  –  coupled receptor agonists 
(ADP or thrombin) and observed normal aggregation responses 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20080240/DC1; and not depicted). 
  The fact that the Y145F platelets responded, albeit less 
well, to collagen but not to CVX suggests that the function of 
the integrin     2    1 may be retained in the setting of this SLP76 
mutation. To test     2    1 function in platelets from the SLP76 
KI mice, we used a blocking mAb directed against the     2 
component of the integrin. Although blocking     2    1 on WT 
platelets resulted in slightly delayed aggregation to collagen 
(  26  ), this same treatment completely inhibited the collagen 
response of Y145F platelets, even at high collagen concentra-
tions (  Fig. 2 E  ). Y112/128F platelets showed an intermediate 
phenotype in which inhibition of     2    1 signifi  cantly reduced 
but did not completely abrogate the collagen response. These 
results indicate that aggregation of SLP76 KI platelets to 
higher doses of collagen relies on     2    1. Thus, the abnormal 
aggregation phenotype of the mutant platelets appears to be 
caused by decreased signaling via GPVI in Y112/128F plate-
lets and a complete lack of this response in Y145F platelets. 
       Granule secretion and     IIb    3 activation are reduced 
in Y112/128F and severely defective in Y145F platelets 
  After GPVI stimulation, platelet aggregation is accompanied 
by secretion of      granule contents. To further characterize 
the signaling capacity of GPVI in SLP76 KI platelets, we 
studied induced surface expression of P-selectin in response 
to GPVI activation. Consistent with previous results (  7  ), 
SLP76      /      platelets failed to up-regulate P-selectin expres-
sion after GPVI stimulation, whereas WT cells showed a 
dose-dependent response (  Fig. 3 A  ).   Y112/128F platelets 
demonstrated a moderate decrease (40  –  50% of control) in 
induced P-selectin expression with a range of CVX concen-
trations, whereas secretion in Y145F cells was reduced 
  >  80%. All platelets responded to AYPGKF, a protease apop-
tosis response 4 receptor agonist that activates platelets in an 
SLP76-independent manner. 
  Increased fi  brinogen binding to     IIb    3 is also critical for 
platelet aggregation. GPVI stimulation generates a signal that 
induces a conformational change in     IIb    3, increasing its af-
fi  nity for fi  brinogen. To investigate the contribution of SLP76 
tyrosines to GPVI-induced     IIb    3 activation, platelets from 
WT or SLP76 KI mice were stimulated with CVX in the 
presence of soluble fl  uorophore-conjugated fi  brinogen. Rest-
ing platelets from all mice bound fi  brinogen poorly (  Fig. 3 B  ). 
Similar to what we observed for P-selectin up-regulation, the 1780 SLP76 TYROSINES IN PLATELET FUNCTION   | Bezman et al. 
exhibited no enhancement of Btk phosphorylation in CVX-
stimulated platelets. Y112/128F and Y145F platelets showed 
a signifi  cant reduction in inducible Btk phosphorylation (  Fig. 
4 E  ). These results suggest that SLP76, particularly its N-ter-
minal tyrosines, potentiates GPVI-induced PLC    2 activation 
by regulating phosphorylation of Btk. 
  Tyrosines 112 and 128 of SLP76 have been shown, in 
Jurkat T cells, to be the sites responsible for Vav association 
(  12, 14, 31  ). Vav proteins have also been demonstrated to 
be necessary for optimal phosphorylation and activation of 
PLC    2 after GPVI stimulation in platelets (  32  ). Based on 
these observations, we reasoned that in Y112/128F mice, 
Vav/SLP76 binding would be abolished and Vav phosphoryl-
ation might also be reduced. We were surprised to fi  nd that 
the Vav1/SLP76 association and Vav1 phosphorylation were 
preserved in Y112/128 platelets (  Fig. 4 F   and not depicted). 
Interestingly, we observed that there was a near complete loss 
of Vav1 phosphorylation in Y145F platelets. 
phosphorylation in KI cells. When platelets are activated with 
escalating doses of CVX (0.4  –  1 nM), there is a dose-depen-
dent increase in PLC    2 phosphorylation in WT and mutant 
platelets (  Fig. 4 D  ). However, although Y145F platelets ex-
hibit defective PLC    2 phosphorylation at all agonist doses, 
high CVX concentrations induce levels of phospho-PLC    2 in 
Y112/128F platelets near those produced in WT cells. 
  Btk has been implicated as the major kinase responsible 
for PLC    2 phosphorylation during GPVI signaling (  28  ). 
Given that the proposed binding site for the Btk homologue 
Itk is Y145 of SLP76 and that its kinase activity depends on 
SLP76 N-terminal tyrosines in Jurkat T cells (  29  ), we hy-
pothesized that SLP76 tyrosines contribute to the regulation 
of PLC    2 phosphorylation in platelets by facilitating the acti-
vation of Btk. We immunoprecipitated Btk from resting or 
stimulated platelets and measured its tyrosine phosphoryl-
ation status, an indicator of activation (  30  ). In contrast to the 
prominent Btk phosphorylation in WT cells, SLP76      /      cells 
    Figure 3.     Secretion and fi  brinogen-binding defects in SLP76 KI platelets in response to CVX.   (A) P-selectin surface expression was analyzed by 
fl  ow cytometry after stimulation with 0.2 nM or 1 nM CVX, or 1 mM AYPGKF. Representative histograms are shown. (B) Platelets were treated as de-
scribed in A and were stained with 100   μ  g/ml of Alexa Fluor 647  –  labeled fi  brinogen. EDTA was added to control for nonspecifi  c binding. Mean percent-
ages   ±   SEM of P-selectin  –  positive (A) or fi  brinogen-bound (B) cells after the indicated stimulations (  n   = 4  –  6 mice per genotype) are shown. *, P   <   0.01.     JEM VOL. 205, August 4, 2008 
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were required for cytoskeleton reorganization during platelet 
spreading on collagen. Platelets from WT or SLP76 KI mice 
were plated onto slides coated with fi  brillar collagen, and 
morphological changes were examined by staining cells with 
rhodamine-phalloidin. WT platelets spread, forming exten-
sive lamellipodia upon adhesion to a collagen surface (  Fig. 
5 B  ). There was a marked reduction in the formation of lamelli-
podia with Y112/128F or Y145F platelets, resulting in de-
creased spreading (  Fig. 5 B  ). Full spreading is restored in the 
SLP76 mutants by the addition of ADP (unpublished data). 
These results demonstrate that SLP76 tyrosines link GPVI 
signaling to actin polymerization and platelet spreading. 
  Roles of SLP76 tyrosines in outside-in signaling 
  Fibrinogen binding to     IIb    3 triggers outside-in signals that 
lead to actin reorganization to ensure effi   cient platelet aggre-
gation and spreading. To investigate the role of SLP76 tyro-
sines for this function, we studied the requirements of Y112, 
Y128, and Y145 in signaling by     IIb    3. To examine whether 
SLP76 tyrosines are phosphorylated in response to integrin 
engagement, we examined the phosphorylation status of the 
various mutants after the attachment of platelets to fi  brinogen. 
    IIb    3 induced an increase in WT SLP76 tyrosine phosphoryl-
ation as assessed by 4G10 (  Fig. 6 A  , lane 2).   Phosphorylation of 
SLP76 Y112/Y128F was detectable but decreased, indicating 
  SLP76 tyrosines link GPVI signaling to actin assembly 
and platelet spreading 
  SLP76 has been implicated in GPVI-induced actin poly-
merization. Resting platelets adopt a spherical discoid shape 
(  Fig. 5 B  ; and see   Fig. 6 B  ).   Upon GPVI stimulation, the 
cells rapidly spread, a process that is accompanied by actin 
polymerization (  Fig. 5, A and B  ). Consistent with the role of 
SLP76 in GPVI signaling, actin assembly was shown to be 
markedly reduced in SLP76      /      platelets activated with the 
GPVI agonist collagen-related peptide (  23  ). Furthermore, in 
the absence of SLP76, platelets fail to spread on a collagen 
matrix (  7  ). To test the requirement for SLP76 tyrosines in 
these processes, we stimulated platelets with CVX and ana-
lyzed actin polymerization quantitatively using fl  uorescently 
labeled phalloidin, which binds to F-actin. GPVI stimulation 
in WT platelets induced a reproducible increase in F-actin 
content above resting levels (  Fig. 5 A  ). In contrast, both 
Y112/128F and Y145F platelets showed only a mild change 
in F-actin staining (  Fig. 5 A  ). These data demonstrate that 
GPVI-induced actin assembly in platelets is dependent on 
SLP76 Y112, Y128, and Y145 residues, consistent with actin 
polymerization defects observed in T cells from these mice 
after TCR ligation (  24  ). 
  To extend these studies to a physiologically relevant 
platelet response, we examined whether Y112/128 or Y145 
    Figure 4.     Optimal phosphorylation of SLP76, Btk, and PLC    2 is dependent on synergy between Y112, Y128, and Y145 during GPVI signal-
ing.   Washed platelets from various mouse strains were left unstimulated (    ) or stimulated with 0.8 nM CVX (+) for 90 s (A and C  –  F) or for 30 and 90 s 
(B) in the presence of apyrase. Equal amounts of platelet lysates were used for immunoblotting or IP. (A) Total SLP76 phosphorylation was measured by IP 
with an SLP76 antibody followed by blotting with 4G10 antibody, whereas phosphorylation of SLP76 Y128 was measured with a phospho-Y128 antibody. 
In both cases, blots were reprobed for total SLP76. (B) Platelet lysates were probed for phospho-Syk (Y525/526) or phospho-LAT (Y191) and reprobed with 
actin as a loading control. (C) PLC    2 phosphorylation was detected by IP with 4G10, followed by immunoblotting with anti-PLC    2 or by immunoblotting 
with phospho-PLC    2 antibody (Y1217). (D) Platelets were stimulated with increasing doses of CVX, and lysates were analyzed for pPLC    2. (E) Btk phos-
phorylation was assessed by IP with anti-Btk antibody and blotting with 4G10 antibody. Total Btk was used as a loading control. (F) Vav1 phosphorylation 
was assessed by IP with anti-Vav1 antibody and blotting with 4G10 antibody. Total Vav was used as a loading control. Quantifi  cation of the Western blot 
band intensities in unstimulated and stimulated samples (B and C) is shown relative to the corresponding loading control.     1782 SLP76 TYROSINES IN PLATELET FUNCTION   | Bezman et al. 
morphology of Y112/128F cells resembled SLP76      /      plate-
lets, with fewer spread cells that remained round, although 
a few fi  lopodial extensions could be seen. Y145F platelets 
showed considerable variability in the spreading response, 
with most cells spreading normally on fi  brinogen. Quantita-
tive analysis of mean platelet surface areas revealed a signifi  cant 
diff  erence only for Y112/128F versus control platelets (  Fig. 
6 C  ). KI platelets spread as well as WT cells when co-stimulated 
with the peptide AYPGKF (  Fig. 6, B and C  ). 
  Platelet adhesion to a fi  brinogen matrix is associated 
with PLC    2 activation and subsequent calcium mobiliza-
tion (  33  ). Because SLP76 is critical for PLC    2 activation after 
GPVI engagement, we assessed whether a defect in PLC    2 
regulation downstream of     IIb    3 could underlie the de-
fective spreading response observed in Y112/128F plate-
lets. WT and SLP76 KI platelets were left unstimulated or 
were stimulated on a fi  brinogen-coated surface and assessed 
for PLC    2 phosphorylation by Western blotting using a 
that Y145 is phosphorylated after     IIb    3 engagement (top 
blot, lane 4). WT but not Y112/128F cells also showed reac-
tivity to anti-pY128 antibody, indicating that Y128 is also 
phosphorylated downstream of     IIb    3 engagement (lanes 2 
and 4). Notably, Y145F platelets showed reduced phosphoryl-
ation of Y128 (bottom blot, lane 6 vs. lane 2). These results 
indicate that SLP76 Y128 and Y145 are phosphorylated after 
    IIb    3 stimulation and that there is an interdependence of 
phosphorylation events at Y145 and Y128, similar to that seen 
downstream of GPVI engagement. 
  To understand the biological implications of SLP76 tyro-
sine phosphorylation, we investigated the eff  ects of SLP76 
  tyrosine mutations on     IIb    3 signaling capacity by analyzing 
platelet spreading on fi  brinogen. Platelets from WT or SLP76 
mutant mice were incubated on a fi  brinogen-coated surface, 
stained with rhodamine-phalloidin, and visualized by micros-
copy. WT platelets underwent spreading, forming fi  lopodia 
and limited lamellipodia (  Fig. 6 B  , middle). In contrast, the 
    Figure 5.     Effect of SLP76 mutations on GPVI-induced F-actin assembly and platelet spreading on collagen.   (A) Histograms with numbers indicating 
the mean fl  uorescence intensity of F-actin levels in unstimulated (gray) and CVX-treated (continuous line) platelets are shown. The data are representative of 
two experiments, each with two animals per genotype. (B) Platelet spreading on BSA (top) or collagen-coated (bottom) surfaces. Platelets were fi  xed, stained for 
F-actin, and analyzed by microscopy. Results shown are representative of fi  ve experiments. Spreading was quantifi  ed by a computer analysis of platelet surface 
areas (graph). Error bars represent the mean   ±   SD, where 35  –  100 platelets were analyzed. *, P   <   0.0001 between Y112/128F, Y145F, and WT platelets. Bar, 10   μ  m.     JEM VOL. 205, August 4, 2008 
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sion of Y112/128F or Y145F platelets to fi  brinogen resulted 
in relatively normal levels of phospho-PLC    2, with only a 
mild reduction seen in Y145F cells (  Fig. 6 E  ). Given that 
phospho-specifi  c PLC    2 antibody. WT platelets exhibited a 
robust increase in the phosphorylation of PLC    2, which was 
signifi  cantly reduced in SLP76      /      platelets (  Fig. 6 D  ). Adhe-
    Figure 6.     SLP76 Y112 and Y128 are necessary for platelet spreading on fi  brinogen but dispensable for PLC    2 phosphorylation downstream 
of     IIb    3.   (A, D, and E) Washed platelets from SLP76 mutant or WT mice were applied to fi  brinogen-coated dishes for 30 min at 37  °  C. Nonadherent 
platelets were removed, and adherent cells were lysed. Resting samples were obtained by lysing platelets in suspension from BSA-coated dishes (   ). 
Tyrosine phosphorylation of SLP76 was assessed by IP with 4G10 antibody, followed by immunoblotting with an anti-SLP76 antibody. Phosphorylation of 
SLP76 Y128 (A), PLC    2 Y1217 (D and E), or Syk (E) was assessed using phospho-specifi  c antibodies. Protein loading was measured by reblotting for actin 
(A), p38 (D), or PLC    2 (E). Values below each band in D and E indicate the quantifi  cation of band intensity relative to the loading control and are repre-
sentative of two and fi  ve experiments, respectively. (B) Platelet spreading on BSA (top), on fi  brinogen alone (middle), or in the presence of 0.25 mM AYP-
GKF peptide (bottom). Cells were stained with rhodamine-phalloidin and analyzed by microscopy. Spreading was quantifi  ed by a computer analysis of 
platelet surface areas. Error bars represent the mean   ±   SD from a representative experiment (  n   = 3) where   ≥  143 platelets were analyzed. **, P   <   0.0001 
between Y112/128F and WT platelets and between SLP76     /     and WT platelets. Bar, 10   μ  m.     1784 SLP76 TYROSINES IN PLATELET FUNCTION   | Bezman et al. 
    DISCUSSION   
  Activation of platelets and their subsequent incorporation 
into a developing thrombus require the orchestration of nu-
merous signaling pathways. SLP76 was shown to be central 
for platelet activation in vitro, but its role in vivo was un-
known. In this study, we show that mice containing muta-
tions in SLP76 tyrosines manifest signifi  cant alterations in 
signaling downstream of collagen receptor GPVI and integ-
rin     IIb    3 in vitro and are protected, to varying degrees, 
from thrombus formation in vivo. 
PLC    2 phosphorylation is normal in Y112/128F cells exhib-
iting impaired spreading, it appears that additional signals are 
required for platelet spreading on fi  brinogen. 
  SLP76 tyrosine mutants do not complement each other 
in trans 
  Our original mutagenesis strategy involved altering both 
Y112 and Y128 to phenylalanine in one mouse and altering 
Y145 alone in a second mouse, because tyrosines 112 and 
128 are found within a similar YESP motif, whereas tyrosine 
145 is found within a YEPP motif. Studies in Jurkat T cells 
showed that Y112 and Y128 together are responsible for 
interactions with Vav and noncatalytic region of tyrosine ki-
nase, whereas Y145 appears most important for its interac-
tion with Tec family PTKs. As shown in this paper, platelets 
from Y112/128F and Y145F mice exhibit abnormalities in 
key SLP76-dependent signaling pathways. We wondered if 
the defects in the signaling pathways observed in platelets 
from the individual KI animals could be rescued by expression 
of the complementary mutation. We bred mice carrying the 
Y112/128F allele with mice carrying the Y145F allele to 
generate animals that were heterozygous for each mutation 
but null for WT SLP76. Experiments were then performed 
examining the GPVI signaling phenotype of the single- or 
double-mutant platelets. 
  As shown earlier, homozygous KI mice have diminished 
GPVI-induced P-selectin expression upon stimulation with 
CVX (  Fig. 7 A  ).   Coexpression of both mutant molecules in 
the same mouse failed to restore this GPVI-mediated response. 
Quantitative comparison of P-selectin up-regulation in the 
various mutant platelets revealed a 50% decrease in inducible 
expression in the double mutant compared with that of the 
Y112/128F cells. Because double-mutant platelets showed a 
response that was intermediate between platelets with two 
copies of Y112/128F and platelets with two copies of Y145F 
alleles, we tested whether this outcome could be caused by a 
dose eff  ect of SLP76 expression. We generated mice express-
ing one null allele and one copy of either the Y145F or the 
Y112/128F allele and compared platelet responses from these 
mice with those of the single- or double-mutant cells. Quan-
tifi  cation of cells staining positive for P-selectin after GPVI 
stimulation showed that platelets from the double mutant re-
sponded equivalently to those from mice with one null allele 
and one Y112/128F allele (Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20080240/DC1). 
  Having established that Y145F and Y112/128F mutants 
do not cooperate with each other in trans to support degran-
ulation, we asked if other GPVI-mediated responses could be 
complemented by expressing both mutants in the same 
mouse. Our fi  ndings indicate that the double-mutant platelets 
do not have improved GPVI-mediated responses compared 
with Y112/128F platelets when     IIb    3 activation is assessed 
(  Fig. 7 B  ), aggregation to CVX or collagen is measured (  Fig. 
7 C  ), or PLC    2 phosphorylation is assayed (  Fig. 7 D  ). These 
results suggest that phosphorylation of tyrosines on a single 
SLP76 molecule is required to support GPVI function. 
    Figure 7.     Coexpression of the complementary SLP76 tyrosine mu-
tants does not reconstitute GPVI signaling.   Platelets from homozy-
gous KI Y112/128F or Y145F mice were compared with platelets isolated 
from animals expressing both Y112/128F and Y145F alleles in assays of 
GPVI activation, as described in   Figs. 2  –  4  . Double-mutant platelets do not 
show an improvement of GPVI-mediated responses compared with those 
of Y112/128F platelets in the assays of (A)      granule secretion, (B) soluble 
fi  brinogen binding, (C) aggregation to 0.4 nM CVX (top) or 5   μ  g/ml col-
lagen (bottom), or (D) phosphorylation of PLC    2. Each panel depicts the 
representative results of two or three experiments.     JEM VOL. 205, August 4, 2008 
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indicate that Vav1 phosphorylation was diminished in Y112/
128F downstream of     IIb    3 engagement. Vav1      /     Vav3      /      
platelets exhibit reduced spreading on fi  brinogen (  36  ), con-
sistent with our fi  ndings. We speculate that SLP76 via Y112 
and/or Y128 may help recruit Vav proteins to     IIb    3, where 
they can be phosphorylated by Syk and facilitate actin re-
organization. It is intriguing to speculate that defective plate-
let spreading might account for the smaller aggregate size in 
Y112/128F platelets compared with WT in an in vitro throm-
bus formation assay. 
  Comparing biochemical and functional readouts of GPVI 
and     IIb    3 signaling, we fi  nd that the mutant that exhibits 
more profound GPVI signaling defects (Y145F) also shows a 
more severe thrombosis defect. These results agree with evi-
dence indicating a signifi  cant role for GPVI signaling in col-
lagen-mediated platelet activation in vivo (  25, 37  ). There is 
also compelling evidence that     IIb    3 is important for throm-
bus formation, because mice defi  cient in     3 integrin are pro-
tected against thrombosis (  38  ). Studies of Y112/128F platelets 
indicate that although it is necessary for fi  brinogen-depen-
dent platelet spreading, the role of SLP76 in outside-in signaling 
by     IIb    3 appears less important for thrombus formation. 
Further studies are necessary to evaluate the contributions of 
SLP76-dependent signals downstream of GPVI versus    IIb    3 
to platelet activation in vivo. 
  The generation of mice containing complementary mu-
tants of SLP76 provided a unique opportunity to study SLP76 
functions in vivo. Our simplistic prediction was that two 
SLP76 molecules with complementary phosphorylation sites 
would become part of a larger signaling network and com-
plement each other in trans, thus rescuing the defective func-
tional responses seen in platelets that express either Y112/128F 
or Y145F. We found that Y112/128F and Y145F mutants 
do not complement each other during GPVI signaling. One 
potential explanation for this lack of cooperation is that mu-
tations in individual tyrosines disrupt phosphorylation of 
the adjacent sites, thus making complementation improbable. 
Indeed, our results suggest that phosphorylation of SLP76 ty-
rosines occurs in a coordinated fashion, demonstrating inter-
dependence between Y128 and Y145 sites. 
  In contrast to the lack of complementation in platelets, 
coexpression of Y112/128F and Y145F mutants within the 
T cell compartment rescues the defective T cell development 
and function found in the individual Y112/128F or Y145F 
mice (  24  ). One potential explanation for the diff  erence be-
tween T cells and platelets is the mechanism by which ITAMs 
of the GPVI or TCR are coupled to an SLP76-nucleated 
complex. Although both SLP76 and LAT are essential for 
TCR signaling, SLP76 can support signaling downstream of 
GPVI in the absence of LAT (  26  ). A recent report (  39  ) dem-
onstrated that LAT oligomerizes after TCR cross-linking, 
which could allow for the transactivation of the signaling 
proteins associated with LAT, such as SLP76. LAT clustering 
has not been shown in platelets. Alternatively, the number of 
ITAMs available to support signaling in T cells (10 ITAMs) 
versus platelets (2 ITAMs) may allow for the formation of a 
  Mobilization of intracellular Ca  2+   and the duration of 
Ca  2+   signaling have been shown to play critical roles in plate-
let secretion, integrin activation, and the formation of stable 
platelet aggregates in fl  owing blood (  34  ). Y145F and Y112/
128F KI platelets exhibit impaired secretion and aggregation 
responses and form smaller thrombi under fl  ow. The reduc-
tion in PLC    2 phosphorylation observed in KI platelets after 
GPVI stimulation suggests that compromised Ca  2+   signaling 
could underlie these functional defects. 
  Based on studies in cell lines from several laboratories 
(for review see reference   35  ), a model emerged positing that 
Y112 and Y128 are both required for SLP76 to associate 
with Vav and that Tec family PTKs bind to Y145; however, 
there are other domains of SLP76 that may contribute to 
this interaction (  17  ). We predicted that SLP76 isolated from 
the Y112/128F mice would not associate with Vav and that 
the interaction between Y145F SLP76 and Itk in T cells or 
Btk in platelets would be diminished. Therefore, we were 
surprised to fi  nd no evidence of diminished binding be-
tween the tyrosine mutants of SLP76 and their binding part-
ners, either in T cells (  24  ) or in platelets. Thus, we focused 
on whether the SLP76 partner proteins Btk and Vav were 
modifi  ed after GPVI stimulation. 
  We examined inducible Btk phosphorylation in platelets 
from WT and SLP76 mutant mice. The absence of SLP76 
results in a marked reduction in GPVI-stimulated phosphoryl-
ation of Btk (  Fig. 4  ), suggesting failed induction of its enzy-
matic activity (  30  ), and inducible Btk phosphorylation was 
only marginally rescued by the expression of SLP76 Y145F. 
Thus, we speculate that one possible mechanism by which 
SLP76 tyrosines regulate PLC    2 activation and intracellular 
Ca  2+   is by aff  ecting GPVI-induced Btk activity. If a major 
function of Y145F is to facilitate Btk activation, the signaling 
phenotype of Y145F platelets should be similar to Btk      /      or 
to mice that are defi  cient in both Btk and its family member 
Tec. Indeed, although Btk      /      platelets are not as defective as 
Y145F platelets in response to GPVI (  28  ), Btk      /     Tec      /      
platelets have a phenotype similar to that of Y145F mice. 
  In contrast to Y145F cells, platelets expressing Y112/
Y128F show only mild defects in GPVI-mediated platelet ac-
tivation. The fact that phosphorylation of Btk was also dimin-
ished in Y112/128F cells suggests that another biochemical 
event may be diff  erentially preserved in these cells. We de-
tected a selective loss of Vav phosphorylation in Y145F but 
not in Y112/128F platelets stimulated via GPVI. Vav plays a 
critical role in platelet activation, at least in part by regulating 
GPVI-induced PLC    2 phosphorylation (  32  ). These results were 
surprising, as we predicted that Vav phosphorylation may 
be preserved in Y145F platelets and absent in Y112/128F 
platelets, as seen in the T cell compartment of these mice (  24  ). 
Although the cause of the reduced Vav phosphorylation in 
Y145F and not Y112/128F mice remains unknown, this de-
fect likely contributes to the diff  erential impairment of GPVI 
signaling observed in Y145F versus Y112/128F platelets. 
  The most severe phenotype of Y112/128F platelets was 
in outside-in signaling by     IIb    3. Our preliminary studies 1786 SLP76 TYROSINES IN PLATELET FUNCTION   | Bezman et al. 
with phalloidin-A594 (Invitrogen). Samples were analyzed on a FACSCali-
bur (BD Biosciences) using FlowJo software (Tree Star, Inc.). 
  Platelet aggregation.     Stimulation of PRP (2.5   ×   10  8   cells/ml) with vari-
ous concentrations of CVX, collagen, or ADP was performed in an ag-
gregometer (model 460-VS; Chrono-Log) with stirring at 37 °  C. Aggregation 
was monitored by measuring changes in light transmission. For the inhibition 
studies, PRP was incubated with 30   μ  g/ml Ha1/29 blocking antibody (BD 
Biosciences) or DMSO for 30 min before the experiment. 
  Immunofl  uorescence.     20   ×   10  6   purifi  ed platelets were added to slides 
coated with 10 mg/ml BSA, 50   μ  g/ml collagen, or 100   μ  g/ml fi  brinogen 
and allowed to spread for 45 min at 37  °  C. In control experiments, platelets 
were allowed to spread in the presence of AYPGKF peptide. Slides were 
washed in PBS, and attached platelets were fi  xed with 2% PFA/PBS for 10 
min at room temperature, permeabilized with 0.2% Triton X-100 for 5 min 
at room temperature, and incubated with rhodamine-phalloidin (Invitrogen) 
to stain F-actin. The quantifi  cation of platelet surface area was performed by 
determining the pixel number within each platelet using IP Laboratories 
Scientifi  c Image Processing software (Scanalytics, Inc.). 
  IP and immunoblotting.     For GPVI stimulation, purifi  ed platelets were 
resuspended in Walsh buff  er containing 2 U/ml apyrase and 10   μ  M indo-
methacin, and were stimulated with 0.8 nM CVX (unless otherwise indi-
cated in the fi  gures). Reactions were stopped by the addition of 2  ×   lysis 
buff  er (1% NP-40 containing 1:100 complete protease inhibitor cocktail 
[Roche], 1 mM PMSF, 2 mM NaVO  3  , 10   μ  M NaF, and 10   μ  M sodium 
pyrophosphate). For     IIb    3 stimulation, platelets were added to dishes and 
coated with 10 mg/ml BSA or 100   μ  g/ml fi  brinogen for 30 min at 37  °  C. 
Platelets adherent to fi  brinogen were washed in PBS and solubilized on ice 
in 1  ×   lysis buff  er. Nonadherent cells from BSA plates were sedimented at 
13,000   g   for 10 s and lysed in 1  ×   lysis buff  er. Lysates were centrifuged at 
13,000   g   for 10 min. Protein concentration was quantifi  ed using BCA pro-
tein assay (Thermo Fisher Scientifi  c), and 10  –  20 or 200  –  500   μ  g of lysates 
were used for Western blotting or IP, respectively. The bead pellets were 
washed once with 1  ×   lysis buff  er containing 0.36 M NaCl and twice with 
1  ×   lysis buff  er before 1  ×   sample buff  er was added (Invitrogen). Proteins 
were resolved by SDS-PAGE. 
  Thrombus formation on collagen under fl  ow.     Slides were coated with 
300   μ  g/ml collagen and blocked with denatured BSA. Heparin-anticoagu-
lated whole blood was perfused over the collagen-coated slide at room tem-
perature for 4 min. Subsequently, slides were rinsed with Tyrode  ’  s buff  er for 
10 min. Phase-contrast images were recorded using a microscope (model 
TE-300; Nikon) at diff  erent axial positions corresponding to various shear 
rates using a 10  ×   objective lens with a 1.5 numerical aperture. For analysis 
of surface coverage and thrombus volume, slides were stained with rhoda-
mine-phalloidin and analyzed by confocal microscopy. Quantifi  cation of 
surface coverage was performed on a single frame using IP Laboratories soft-
ware. Thrombus volume was calculated as the summation of partial volumes 
measured from the area occupied by platelet aggregates in each plane of 
Z-stacks using Volocity software (Improvision). 
  Thrombus formation in vivo.     To measure blood fl  ow, a Doppler probe 
was placed around the isolated carotid artery of 8  –  16-wk-old mice anesthe-
tized with sodium pentobarbitone. Vessel wall damage was induced by ap-
plication of a 0.5   ×   1  –  mm paper fi  lter saturated with 10% FeCl  3   for 3 min. 
After removal of the fi  lter paper, the tissue was washed using saline solution 
for 1 min. The time to complete occlusion was calculated from the time the 
fi  lter paper was removed to when blood fl  ow reached 0  –  0.1 ml/min. The 
experiment was terminated at 30 min. 
  Statistical analysis.     Statistical signifi  cance was analyzed using the Student  ’  s 
  t   tests for independent samples, and P   <   0.05 was considered signifi  cant. 
Where applicable, results are shown as the mean   ±   SEM. A comparison of 
larger complex, which might be necessary for the comple-
mentation of these mutations. A similar requirement for 
cis-mediated adaptor function has been demonstrated for 
SLP65  –  B cell linker (a two ITAM  –  containing signaling com-
plex), where two complementary mutations in tyrosines re-
sponsible for binding PLC    2 were not able to complement 
each other to support BCR signaling (  40  ). Thus, SLP76 fam-
ily adapters might function to nucleate a single molecular 
scaff  old, but if organized into larger oligomerized complexes 
and supported by multiple ITAMs, as they potentially are in 
T cells, multiple SLP76 molecules could cooperate in trans. 
  MATERIALS AND METHODS 
  Reagents.     Antibodies were purchased from the following vendors: 4G10 
and Vav1 (Millipore); pSLP76 (Y128; BD Biosciences); mouse SLP76 
(eBioscience); pPLC    2 (Y1217), pSyk (Y525/526), pLAT (Y191), PLC    2, 
and p38 (Cell Signaling Technology); and Syk, PLC    2, Vav, and actin 
(Santa Cruz Biotechnology, Inc.). Btk antibody was a gift of M. Tomlinson 
and J. Bolen (University of Birmingham, Birmingham, England, UK). 
TrueBlot Ig immunoprecipitation (IP) beads and TrueBlot horseradish 
peroxidase  –  conjugated IgGs were obtained from eBioscience. All reagents 
were purchased from Sigma-Aldrich except for the following: type I bo-
vine collagen (Chrono-Log Corp.); fi  brinogen depleted of plasminogen, 
von Willebrand factor, and fi  bronectin (Enzyme Research Laboratories); 
CVX (ALEXIS Biochemicals); and AYPGKF peptide, which was synthe-
sized by the University of Pennsylvania Protein Chemistry Laboratory. 
  Mice.     Y145F and Y112/128F mice were generated as previously described 
(  24  ) and were backcrossed to C57BL/6 mice two to fi  ve times. Mice were 
viable and showed no gross phenotypic abnormalities. To generate com-
pound or hemizygous KI mice, Y145F and Y112/128F homozygous mice 
were bred with each other or with SLP76      /      mice (  6  ). For all experiments, 
littermates were used as WT controls. C57BL/6 mice were obtained from 
Taconic. All mice were housed under pathogen-free conditions at the Uni-
versity of Pennsylvania Animal Facility and were used in accordance with 
National Institutes of Health guidelines and approved protocols from the 
University of Pennsylvania Institutional Review Board committee. 
  Platelet preparation.     Whole blood was anticoagulated using heparin (ag-
gregation studies) or acidic citrate dextrose, followed by dilution in Tyrode  ’  s 
buff  er (137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO  3  , 0.2 mM CaCl  2  , 0.2 
mM MgCl  2  , 0.1% BSA, 0.1% glucose, and 5 mM Hepes [pH 7.4]). Platelet-
rich plasma (PRP) was prepared by centrifugation at 960   g   for 8 min. Puri-
fi  ed platelets were obtained by centrifugation of PRP at 1,500   g   for 10 min 
in the presence of 1 U/ml apyrase, 1   μ  M prostaglandin E1, and 1 mM aspi-
rin. Platelet pellets were resuspended in Walsh buff  er (137 mM NaCl, 2.7 
mM KCl, 1 mM MgCl  2,   5.6 mM glucose, 1 mg/ml BSA, 3.3 mM NaH  2  PO  4  , 
and 20 mM Hepes [pH 7.4]). For hematological analysis, blood was col-
lected into EDTA-coated tubes (Sarstedt) and analyzed by a Hemavet ma-
chine (model HV950FS; Drew Scientifi  c). For fl  ow cytometry, blood was 
collected by retroorbital bleed into heparin-treated tubes (Thermo Fischer 
Scientifi  c) and diluted in Tyrode  ’  s buff  er containing 1 U/ml heparin. 
  Flow cytometry.     10  6   platelets, in the presence of 1 mM Ca  2+  , were stimu-
lated with 0.2  –  1 nM CVX, 0.5  –  1 mM AYPGKF, or 0.1  –  20   μ  M ADP in the 
presence of CD49b-FITC and P-selectin  –  PE (BD Biosciences) or fi  brino-
gen-A647 (Invitrogen) for 20 min at 37  °  C. To ensure specifi  city of fi  brino-
gen binding, platelets were stimulated in the presence of 0.5 mM EDTA. 
For the measurement of GPVI surface expression, platelets were stained with 
anti  –  JAQ-1  –  FITC (Emfret Analytics) or anti  –  rat IgG2a (BD Biosciences) 
antibodies. For the measurement of F-actin levels, platelets (10  8   cells/ml) 
were stimulated with CVX for 2 min at 37  °  C. Cells were fi  xed with 1% 
paraformaldehyde (PFA), permeabilized with 1% Triton X-100, and stained JEM VOL. 205, August 4, 2008 
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